This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farquharson, C. A. J. Articles by Struthers, A. D. Search for Related Content PubMed PubMed Citation Articles by Farquharson, C. A. J. Articles by Struthers, A. D.

Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure

^a University Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, United Kingdom

View larger version (18K): [in a new window]   Figure 1 Forearm blood flow (FBF) responses to angiotensin I and II with regard to New York Heart Association class: I (triangle), II (square) and III (circle). *p < 0.05.

View larger version (17K): [in a new window]   Figure 2 Forearm blood flow (FBF) responses to angiotensin I and angiotensin II at baseline (square), after nine months (triangle) and after 18 months (circle). **p < 0.001.

View larger version (18K): [in a new window]   Figure 3 Forearm blood flow (FBF) responses to angiotensin I and angiotensin II with differing dosages of angiotensin-converting enzyme inhibitors: lisinopril 10 mg/day (square), lisinopril 5 mg/day (triangle) and lisinopril 20 mg/day (circle). **p < 0.001.

View larger version (11K): [in a new window]   Figure 4 Differences in plasma angiotensin II, angiotensin II/I ratios, angiotensin-converting enzyme (ACE) and aldosterone levels according to New York Heart Association class. *p < 0.05.

View larger version (10K): [in a new window]   Figure 5 Changes in plasma levels of angiotensins, aldosterone and angiotensin-converting enzyme (ACE) levels longitudinally with time.

View larger version (10K): [in a new window]   Figure 6 Plasma angiotensins, aldosterone and angiotensin-converting enzyme with changing doses of angiotensin-converting enzyme (ACE) inhibitor.

View larger version (15K): [in a new window]   Figure 7 Comparison of angiotensin I-FBF30% (forearm blood flow) in each subgroup defined in the three studies in patients with chronic heart failure.